Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Rakuten Medical CEO-Elect Reaffirms 2028 US Filing Plan for Akalux
Minami Maeda, who will become CEO of Rakuten Medical’s US headquarters on July 1, says his immediate priority is to secure a US filing in 2028 for ASP-1929, the company’s lead photoimmunotherapy asset marketed in Japan as Akalux. Speaking to…
To read the full story
Related Article
- Rakuten Medical to Promote President Maeda to CEO
June 11, 2026
- Rakuten Ramps Up Photoimmunotherapy PIII with Financing, Eyes US Filing in 2028
January 9, 2026
- Rakuten Launches Japan Arm of Global PIII for Photoimmunotherapy/Keytruda Combo
July 30, 2025
- Rakuten Medical Launches Global PIII Trial of Photoimmunotherapy/Keytruda Combo
January 27, 2025
- Rakuten Medical Ratcheting Up Overseas Expansion Drive for Akalux: Japan Chief
April 25, 2024
BUSINESS
- MSD Urges Swift Rollout of Routine HPV Vaccination for Males in Japan
July 29, 2026
- Drug Makers, Wholesalers Rush to Gauge Kumamoto Quake Impact
July 29, 2026
- Takeda Files Entyvio IV for Pediatric Use, New Adult Dosing in Japan
July 29, 2026
- Otsuka Ups 1H Guidance on Strong Sales, Delayed Generic Competition
July 29, 2026
- Japan OTC Market Falls for 4th Straight Month in June: Intage
July 29, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…